- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05040074
SQ-Kyrin TMVr FIM Study
SQ-Kyrin Transcatheter Mitral Valve Repair System Feasibility Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Grace Gu
- Phone Number: 13636491192
- Email: guchaojun@sqmedical.com
Study Locations
-
-
Liaoning
-
Shenyang, Liaoning, China, 123005
- Recruiting
- General Hospital of Northern Theater Command, PLA
-
Contact:
- Yaling Han, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Severe mitral valve regurgitation ≥ 3+ (moderate-to-severe mitral regurgitation disease);
Patients with high or prohibitive risk for conventional open thoracic surgery as defined by STS risk scoring result; subjects who are judged as not tolerating mitral valve surgery due to STS procedural mortality risk ≥ 8% for mitral valve replacement or presence of any of the following risk factors:
- Porcelain aorta or active ascending aortic atheroma
- Prior radiation therapy to mediastinum
- History of mediastinitis
- Left ventricular ejection fraction (LVEF) < 40%
- Presence of unobstructed coronary artery bypass graft
- History of 2 or more cardiothoracic surgeries
- Liver cirrhosis
- Other surgical risk factors
- Degenerated MR patients, or functional MR patients who have received guideline-directed medical therapy (GDMT therapy)
- Age ≥ 18 years, male or female;
- Patients who are at extremely high risk or not suitable for conventional mitral valve surgery, as assessed by a multidisciplinary heart team (including at least one cardiac surgeon and one cardiologist);
- Anatomically suitable for transcatheter mitral valve repair by edge-to-edge technique and can be treated by the SQ-Kyrin device;
- Patients who can understand the objectives of the trial, volunteer to participate in the study, sign the informed consent form, and are willing to receive related examinations and clinical follow-up.
Exclusion Criteria:
- History of cardiac and mitral valve surgeries;
- Infective endocarditis or evidence of active infection;
- Mitral valve stenosis;
- Severe uncontrolled coronary artery disease;
- Pulmonary artery hypertension (systolic pulmonary artery pressure > 70 mmHg);
- Severe right cardiac insufficiency;
- LVEF < 30%;
- Cardiac function of NYHA Class IV;
- Patient is extremely week to tolerate surgery under general anesthesia, or in a shock state indicating circulatory support;
- Hypertrophic cardiomyopathy, restrictive cardiomyopathy, or constrictive pericarditis;
- Chronic dialysis;
- Definite coagulation disorder and severe coagulation system diseases;
- Clear contraindications for use of anticoagulants;
- Cerebral stroke or transient ischemic attack in the past 30 days;
- Any cardiac mass, left ventricular or atrial thrombosis identified by echocardiography;
- Other valve diseases that requiring surgery or intervention;
- Severe macrovascular disease requiring surgical treatment;
- Treatment-naive carotid artery stenosis > 70%;
- Imaging evidence of inappropriate cardiac and valve anatomy;
- Known hypersensitivity to contrast media, and nickel-titanium memory alloy products;
- Severe nervous system disorder compromising the cognitive ability;
- Life expectancy < 12 months;
- Severe thorax deformity;
- Pregnant and lactating women.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SQ-Kyrin TMVr Feasibility Study
Experimental group is allocated to use the transcatheter edge-to-edge valve repair system of Shanghai Shenqi Medical Technology Co., Ltd.
|
Transesophageal echocardiography-guided, implantable mitral valve clip repair system
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of acute procedural success
Time Frame: Immediate postoperative
|
Must meet all the four items:1)no procedural mortality; 2)success in delivery and retrieval of the device delivery system; 3)successful deployment and accurate positioning of the device; 4)no emergency surgery or reintervention related to the device or surgical approach
|
Immediate postoperative
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
All-cause mortality
Time Frame: 1 month
|
Death from any cause
|
1 month
|
Incidence of serious adverse event(SAE)
Time Frame: 1 month
|
If the adverse event meets any of the criteria below, it is regarded as a serious adverse event (SAE): 1) results in death; 2) is life threatening, results in illness or injury; 3) requires inpatient hospitalization or prolongation of existing hospitalization; 4) results in a persistent or significant disability/incapacity; 5) results in a congenital anomaly/birth defect, fetal death, fetal distress; 6) results in medical or surgical intervention to prevent permanent impairment to body structure or a body function; 7) an important medical event that may not result in death, be life-threatening, or require hospitalization but may be considered serious when, based upon appropriate medical judgment, may jeopardize the patient or subject and/or may require intervention to prevent one of the outcomes listed in this definition.
|
1 month
|
Device success rate
Time Frame: 1 month
|
Definition of device success(must meet all the four items) :1) No procedural mortality or stroke;2) Proper deployment and positioning of the device;3) No emergency surgery or reintervention related to the device or surgical approach;4) The implanted mitral valve repair system achieves the following safety and effectiveness indicators:
|
1 month
|
Procedural success rate
Time Frame: 1 month
|
Definition of procedural success(must meet the two items):1) Device success;2) Absence of the following severe complications: death; stroke; life-threatening hemorrhage; severe vascular complications; secondary severe organic heart diseases (e.g.: aortic dissection, left atrium/auricle rupture, left ventricular outflow tract obstruction, etc.); Grade II-III and above renal insufficiency; myocardial infarction or coronary ischemia requiring percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG); severe hypotension, heart failure, respiratory failure requiring use of high-dose vasoactive medications/mechanical acids; any valve-related dysfunctions, including repair device detachment (single or two valve leaflets)/embolism/device-related autologous mitral valve damage/other conditions requiring second intervention.
|
1 month
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- VRP01-001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mitral Regurgitation
-
Abbott Medical DevicesCompletedFunctional Mitral Regurgitation | Degenerrative Mitral RegurgitationRussian Federation
-
Ancora Heart, Inc.CompletedMitral Regurgitation | Mitral Valve Regurgitation | Functional Mitral RegurgitationAustria, Lithuania, Germany
-
Heinrich-Heine University, DuesseldorfCompletedMitral Regurgitation | Functional Mitral Regurgitation | Degenerative Mitral Valve RegurgitationGermany
-
Mitre Medical Corp.BSWRI Cardiac Imaging Core Lab (CICL)Not yet recruitingIschemic Mitral Regurgitation | Functional Mitral RegurgitationUnited States
-
Abbott Medical DevicesCompletedMitral Valve Regurgitation | Mitral Valve Incompetence | Mitral Insufficiency | Functional Mitral Regurgitation | Mitral Stenosis With InsufficiencyJapan
-
Hospital Clinic of BarcelonaAbbottUnknownMITRAL REGURGITATIONSpain
-
Edwards LifesciencesRecruitingMitral Regurgitation | Mitral Insufficiency | Functional Mitral Regurgitation | Degenerative Mitral Valve DiseaseUnited States, Canada, Switzerland, Germany
-
Boston Scientific CorporationActive, not recruitingCardiovascular Diseases | Mitral Regurgitation Functional | Mitral Valve DiseaseUnited States, Australia
-
Abbott Medical DevicesActive, not recruitingHeart Failure | Mitral Regurgitation | Mitral Valve Regurgitation | Treatment of Functional Mitral Regurgitation in Symptomatic Heart Failure SubjectsUnited States, Canada
-
Mardil MedicalRecruitingFunctional Mitral RegurgitationCanada, Hungary, France, Germany, Netherlands, Panama, Poland
Clinical Trials on SQ-Kyrin Transcatheter Edge-to-Edge Valve Repair System
-
Helios Klinikum PforzheimRecruitingRight Heart Failure | Tricuspid Regurgitation | Cardiac Remodeling, Ventricular | Cardiac Remodeling, AtrialGermany
-
Xiamen Cardiovascular Hospital, Xiamen UniversityRecruiting
-
LMU KlinikumRecruitingHeart Failure | Valvular Heart Disease | Tricuspid RegurgitationGermany
-
Shanghai Shenqi Medical Technology Co., LtdActive, not recruitingFunctional Mitral RegurgitationChina
-
Peijia Medical Technology (Suzhou) Co., Ltd.RecruitingMitral Regurgitation | Degenerative Mitral Valve DiseaseChina
-
Enlight Medical Technologies (Shanghai) Co., LtdActive, not recruitingDegenerative Mitral Valve DiseaseChina
-
Heart Center Leipzig - University HospitalRecruitingCongestive Heart Failure | Tricuspid RegurgitationGermany
-
Annetine GelijnsNational Heart, Lung, and Blood Institute (NHLBI)RecruitingMitral Valve RegurgitationUnited States, Germany, United Kingdom, Canada
-
Istituto Auxologico ItalianoRecruitingTricuspid RegurgitationItaly
-
Deutsches Herzzentrum MuenchenRecruitingMitral Valve Stenosis | Mitral Valve Regurgitation | Tricuspid Valve RegurgitationGermany